Shionogi launches new European headquarters in London

Friday, July 6, 2012 11:47 AM

Japan-based pharmaceutical company Shionogi & Co. has launched its new European headquarters in London, to be called Shionogi Limited.

The new headquarters is part of the company’s five year business plan to expand its business world wide. Shionogi elected to base their European headquarters in London following an extensive review of potential locations on the continent as well as within the U.K. London was chosen by Shionogi because of the good business infrastructure and support, the pool of exceptional talent, a favorable living environment for their employees and easy access to the rest of Europe.

“We are delighted to be launching our new European headquarters in London,” said Takashi Takenoshita, CEO of Shionogi Europe. “We aim to achieve our mission as a company with a strong presence in Europe, which conducts business operations recognized by patients, their families, healthcare providers and broader communities.”

The mayor of London, Boris Johnson, added, “Boosting jobs and growth is my number one priority, and this means attracting ever more companies to the capital. Shionogi will make a fantastic addition to London's growing life sciences sector, which benefits from our top class universities and research centers, direct access to huge markets, a skilled cosmopolitan workforce and fantastic connectivity.”

The company plans to quickly expand the number of employees in London and has recently made several key appointments: Dr. Marco Renoldi, Dr. Suhail Nurbhai, Dr. Mark Sampson, Nina Strenitz and Joe Gaugas.

Dating back to 1878, Shionogi has been involved in research, development, manufacturing and marketing activities for over 130 years. In 1998 Shionogi licensed one of its new molecules that later became Crestorto AstraZeneca and still markets this drug in Japan today. Currently the company has a strong strategic focus on infectious diseases, pain and metabolic syndrome.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs